The inhibiting effect of factor XIII on hyperfibrinolysis

Anesthesia and Analgesia

Volumn 114, Issue 6, 2012, Pages 1149-1150

  Theusinger, Oliver M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 13; CALCIUM; FIBRINOGEN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID;

BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CRITICALLY ILL PATIENT; CRYOPRECIPITATION; EDITORIAL; FIBRINOLYSIS; HUMAN; HYPERFIBRINOLYSIS; IN VITRO STUDY; MORTALITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ANTIFIBRINOLYTIC AGENTS; FACTOR VIIA; FACTOR XIII; FEMALE; FIBRINOLYSIS; HUMANS; MALE; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

EID: 84861525830     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318252e9f1     Document Type: Editorial

References (15)

1. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003;16:17-20
2. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996;16:539-45
3. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009;67:125-31
4. Theusinger OM, Wanner GA, Emmert MY, Billeter A, Eismon J, Seifert B, Simmen HP, Spahn DR, Baulig W. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011;113:1003-12
5. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096 -101, 1101.e1-2
6. Levy JH. Antifibrinolytic therapy: new data and new concepts. Lancet 2010;376:3-4
7. Dirkmann D, Görlinger K, Gisbertz C, Dusse F, Peters J. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Anesth Analg 2012;114:1182-8
8. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006;4:19-25
9. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999;94:271-305
10. Inbal A, Dardik R. Role of coagulation factor XIII (FXIII) in angiogenesis and tissue repair. Pathophysiol Haemost Thromb 2006;35:162-5
11. Francis CW, Marder VJ. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations: role of platelet factor XIII. J Clin Invest 1987;80:1459-65
12. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost 1992;68:315-20
13. Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Thromb Haemost 1996;75:161-7
14. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in rotation thromboelastometry (ROTEM). Thromb Haemost 2010;104:385-91
15. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988;71:1361-5